Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of March 29, 2025 • 10:00 AM ET

Date/Time Source News Release
03/26/2025 08:40 AM EDT GlobeNewswire Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
02/26/2025 01:30 PM EST GlobeNewswire Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
02/18/2025 08:50 AM EST GlobeNewswire Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
02/11/2025 07:45 AM EST GlobeNewswire Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
01/22/2025 08:29 AM EST GlobeNewswire Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
01/08/2025 08:29 AM EST GlobeNewswire Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
01/02/2025 08:45 AM EST GlobeNewswire Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
12/18/2024 07:35 AM EST GlobeNewswire Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
11/29/2024 08:05 AM EST GlobeNewswire Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
11/18/2024 08:40 AM EST GlobeNewswire Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
Page

Additional News

As of March 29, 2025 • 10:00 AM ET

Date/Time Source News Release
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.